Consensus NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
2.18 ^USD	-15.50%		-30.13%	-52.61%

04-30	NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression	CI
04-18	NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq	MT

Evolution of the average Target Price on NRx Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6723f4e8ed2ff3deb3101ddc7c3.em6wUccQJ3xg91s6rC_y9AiYuOYs5sTw2LL0TcPH7rk.CkPbELU9VRE2gW1JwWPKglroitRGjZO7jYuWPvSmv-AtN_U6_llyMwGCAg~cb9638538e4c332610e62816764b85ce

Analyst Recommendations on NRx Pharmaceuticals, Inc.

Ascendiant Capital Starts NRX Pharmaceuticals at Buy With $4 Price Target	22-11-09	MT
HC Wainwright Starts NRX Pharmaceuticals at Buy With $2 Price Target	22-06-30	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.18 USD

Average target price

37.5 USD

Spread / Average Target

+1,620.18%

High Price Target

55 USD

Spread / Highest target

+2,422.94%

Low Price Target

20 USD

Spread / Lowest Target

+817.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NRx Pharmaceuticals, Inc.

Ascendiant Capital
HC Wainwright

Quarterly revenue - Rate of surprise

Company calendar